Zimmer Biomet Holdings, Inc. (ZBH)

In the past six months, Zimmer Biomet reported strong second-quarter 2025 results on August 7, 2025, exceeding expectations and leading to a raised full-year guidance. On November 14, 2025, Zimmer Biomet received U.S. FDA clearance for an enhanced version of its ROSA® Knee Robotic Technology. The company announced a partnership with OneStep on December 16, 2025, to provide enhanced mobility data to patients and surgeons. A quarterly dividend for the fourth quarter of 2025 was announced on December 17, 2025. Zimmer Biomet presented at the 44th Annual J.P. Morgan Healthcare Conference on December 22, 2025, and January 13, 2026, where management discussed the company's strategic transformation, new product launches, and a cautious outlook for 2026. On January 7, 2026, Zimmer Biomet inked a partnership with PatientIQ. The company also announced the resignation of executive officer Mark Bezjak, effective January 16, 2026, on January 12, 2026. From January 6, 2025, to January 2, 2026, the share price experienced a decline of 13.07%. Analyst sentiment has been moderately positive, with Evercore ISI upgrading the stock and Bernstein adjusting its price target in early January 2026.

Zimmer Biomet's business experiences some seasonality due to elective procedures declining during the summer and increasing towards the end of the year. The broader medical device industry is poised for steady growth, driven by an aging global population, increasing healthcare expenditures, and continuous technological advancements.

Zimmer Biomet Holdings, Inc. is a global medical technology company specializing in musculoskeletal healthcare, operating in the medical devices and instruments industry. The company designs, manufactures, and markets orthopedic reconstructive products, biologics, sports medicine, extremities, trauma, craniomaxillofacial, and thoracic products, as well as office-based technologies and surgical products. Key products include artificial joints and dental prostheses. Zimmer Biomet integrates digital and robotic technologies, leveraging data analytics and AI to enhance surgical precision, with products like the ROSA Robotics portfolio. The company spun out its dental and spine businesses in 2022.

Zimmer Biomet has a wide global presence, with operations in over 25 countries and sales in more than 100 markets. Its corporate headquarters are located in Warsaw, Indiana, U.S. The company markets its products through direct sales channels and distributors across the Americas, Europe, Asia-Pacific, the Middle East, and Africa.

In November 2025, Zimmer Biomet was named to Forbes' 2026 List of America's Best Companies. Leadership transitions occurred in 2025, with Ivan Tornos being appointed Chairman of the Board in May 2025. The company is also navigating ongoing legal investigations and regulatory compliance environments.

Zimmer Biomet's shareholder base is predominantly institutional, with these investors collectively holding nearly 94% to 97% of the company's stock. Major institutional owners include Vanguard Group Inc., Dodge & Cox, BlackRock, Inc., T. Rowe Price Associates, State Street Corp, Capital International Investors, Geode Capital Management, American Century Investment Management, and Harris Associates. Insider ownership remains relatively modest at approximately 1.39%.